{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:48:04Z","timestamp":1776779284540,"version":"3.51.2"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02816-3","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T08:56:35Z","timestamp":1751532995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of Tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: a post-hoc analysis of pooled data from three phase 3 trials"],"prefix":"10.1186","volume":"24","author":[{"given":"Litong","family":"Qi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beijian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongming","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiufang","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanling","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"issue":"2","key":"2816_CR1","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jdiacomp.2016.10.008","volume":"31","author":"LL Lim","year":"2017","unstructured":"Lim LL, Tan AT, Moses K, Rajadhyaksha V, Chan SP. Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: insights into the management of Asian phenotype. J Diabetes Compl. 2017;31(2):494\u2013503.","journal-title":"J Diabetes Complications"},{"key":"2816_CR2","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843.","journal-title":"Diabetes Res Clin Pract"},{"key":"2816_CR3","doi-asserted-by":"publisher","first-page":"503437","DOI":"10.1016\/j.mrgentox.2021.503437","volume":"874","author":"JE Lima","year":"2022","unstructured":"Lima JE, Moreira NC, Sakamoto-Hojo ET. Mechanisms underlying the pathophysiology of type 2 diabetes: from risk factors to oxidative stress, metabolic dysfunction, and hyperglycemia. Mutat Research\/Genetic Toxicol Environ Mutagen. 2022;874:503437.","journal-title":"Mutat Research\/Genetic Toxicol Environ Mutagen"},{"issue":"18","key":"2816_CR4","doi-asserted-by":"publisher","first-page":"e2100275","DOI":"10.1002\/advs.202100275","volume":"8","author":"S Demir","year":"2021","unstructured":"Demir S, Nawroth PP, Herzig S, Ekim \u00dcst\u00fcnel B. Emerging targets in type 2 diabetes and diabetic complications. Adv Sci (Weinh). 2021;8(18):e2100275.","journal-title":"Adv Sci (Weinh)"},{"key":"2816_CR5","doi-asserted-by":"crossref","unstructured":"Shi LJ, Tang X, He J, Shi W. Genetic evidence for a causal relationship between hyperlipidemia and type 2 diabetes in mice. Int J Mol Sci 2022, 23(11).","DOI":"10.3390\/ijms23116184"},{"key":"2816_CR6","doi-asserted-by":"crossref","unstructured":"Korneva V, Kuznetsova T, Julius U. The role of cumulative LDL cholesterol in cardiovascular disease development in patients with Familial hypercholesterolemia. J Pers Med 2022, 12(1).","DOI":"10.3390\/jpm12010071"},{"issue":"4","key":"2816_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.tcm.2020.03.004","volume":"31","author":"V Bianconi","year":"2021","unstructured":"Bianconi V, Banach M, Pirro M. Why patients with Familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels. Trends Cardiovasc Med. 2021;31(4):205\u201315.","journal-title":"Trends Cardiovasc Med"},{"issue":"3","key":"2816_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.gheart.2018.09.511","volume":"13","author":"H Thomas","year":"2018","unstructured":"Thomas H, Diamond J, Vieco A, Chaudhuri S, Shinnar E, Cromer S, Perel P, Mensah GA, Narula J, Johnson CO, et al. Global atlas of cardiovascular disease 2000\u20132016: the path to prevention and control. Glob Heart. 2018;13(3):143\u201363.","journal-title":"Glob Heart"},{"issue":"4","key":"2816_CR9","doi-asserted-by":"publisher","first-page":"487","DOI":"10.4093\/dmj.2019.0067","volume":"43","author":"BY Kim","year":"2019","unstructured":"Kim BY, Won JC, Lee JH, Kim HS, Park JH, Ha KH, Won KC, Kim DJ, Park KS. Diabetes fact sheets in korea, 2018: an appraisal of current status. Diabetes Metab J. 2019;43(4):487\u201394.","journal-title":"Diabetes Metab J"},{"key":"2816_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-020-01204-y","volume":"19","author":"M Hedayatnia","year":"2020","unstructured":"Hedayatnia M, Asadi Z, Zare-Feyzabadi R, Yaghooti-Khorasani M, Ghazizadeh H, Ghaffarian-Zirak R, Nosrati-Tirkani A, Mohammadi-Bajgiran M, Rohban M, Sadabadi F. Dyslipidemia and cardiovascular disease risk among the MASHAD study population. Lipids Health Dis. 2020;19:1\u201311.","journal-title":"Lipids Health Dis"},{"key":"2816_CR11","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s10389-020-01205-2","volume":"29","author":"AT Bawah","year":"2021","unstructured":"Bawah AT, Darko R, Abaka-Yawson A, Seini MM, Kinanyok S, Adusei S. Dyslipidemia and its associated factors in patients with type 2 diabetes mellitus. J Public Health. 2021;29:985\u201391.","journal-title":"J Public Health"},{"key":"2816_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10741-015-9515-6","volume":"21","author":"TP Patel","year":"2016","unstructured":"Patel TP, Rawal K, Bagchi AK, Akolkar G, Bernardes N, Dias DS, Gupta S, Singal PK. Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes. Heart Fail Rev. 2016;21:11\u201323.","journal-title":"Heart Fail Rev"},{"issue":"2","key":"2816_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.numecd.2022.10.001","volume":"33","author":"A Poli","year":"2023","unstructured":"Poli A, Catapano AL, Corsini A, Manzato E, Werba JP, Catena G, Cetin I, Cicero AFG, Cignarella A, Colivicchi F, et al. LDL-cholesterol control in the primary prevention of cardiovascular diseases: an expert opinion for clinicians and health professionals. Nutr Metab Cardiovasc Dis. 2023;33(2):245\u201357.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"6","key":"2816_CR14","doi-asserted-by":"publisher","first-page":"e008552","DOI":"10.1161\/CIRCOUTCOMES.121.008552","volume":"15","author":"N Wang","year":"2022","unstructured":"Wang N, Woodward M, Huffman MD, Rodgers A. Compounding benefits of Cholesterol-Lowering therapy for the reduction of major cardiovascular events: systematic review and Meta-Analysis. Circ Cardiovasc Qual Outcomes. 2022;15(6):e008552.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"2816_CR15","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s12020-021-02870-3","volume":"75","author":"J Yu","year":"2022","unstructured":"Yu J, Liu X, Chen S, Liu Y, Liu H, Zheng H, Yang N, Wu S, Li Y. Effects of low-density lipoprotein cholesterol on cardiovascular disease and all-cause mortality in elderly patients (\u2265\u200975 years old). Endocrine. 2022;75(2):418\u201326.","journal-title":"Endocrine"},{"issue":"22","key":"2816_CR16","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"5","key":"2816_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrcardio.2011.2","volume":"8","author":"A Brautbar","year":"2011","unstructured":"Brautbar A, Ballantyne CM. Pharmacological strategies for Lowering LDL cholesterol: Statins and beyond. Nat Reviews Cardiol. 2011;8(5):253\u201365.","journal-title":"Nat Reviews Cardiol"},{"key":"2816_CR18","first-page":"73","volume":"270","author":"A Pirillo","year":"2022","unstructured":"Pirillo A, Norata GD, Catapano AL. LDL-Cholesterol-Lowering therapy. Handb Exp Pharmacol. 2022;270:73\u2013101.","journal-title":"Handb Exp Pharmacol"},{"key":"2816_CR19","doi-asserted-by":"publisher","first-page":"839571","DOI":"10.3389\/fcvm.2022.839571","volume":"9","author":"L Bi","year":"2022","unstructured":"Bi L, Yi J, Wu C, Hu S, Zhang X, Lu J, Liu J, Zhang H, Yang Y, Cui J, et al. Atherosclerotic cardiovascular disease risk and Lipid-Lowering therapy requirement in China. Front Cardiovasc Med. 2022;9:839571.","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"2816_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11883-015-0552-3","volume":"17","author":"T Stulc","year":"2015","unstructured":"Stulc T, Ce\u0161ka R, Gotto AM Jr. Statin intolerance: the clinician\u2019s perspective. Curr Atheroscler Rep. 2015;17(12):69.","journal-title":"Curr Atheroscler Rep"},{"key":"2816_CR21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","volume":"290","author":"2019 ESC\/EAS guidelines for the","year":"2019","unstructured":"2019 ESC\/EAS guidelines for the. Management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140\u2013205.","journal-title":"Atherosclerosis"},{"issue":"1","key":"2816_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12916-023-02797-8","volume":"21","author":"M Chai","year":"2023","unstructured":"Chai M, He Y, Zhao W, Han X, Zhao G, Ma X, Qiao P, Shi D, Liu Y, Han W, et al. Efficacy and safety of Tafolecimab in Chinese patients with heterozygous Familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2). BMC Med. 2023;21(1):77.","journal-title":"BMC Med"},{"issue":"4","key":"2816_CR23","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jacasi.2023.04.011","volume":"3","author":"L Qi","year":"2023","unstructured":"Qi L, Liu D, Qu Y, Chen B, Meng H, Zhu L, Li L, Wang S, Liu C, Zheng G, et al. Tafolecimab in Chinese patients with hypercholesterolemia (CREDIT-4): a randomized, Double-Blind, Placebo-Controlled phase 3 trial. JACC Asia. 2023;3(4):636\u201345.","journal-title":"JACC Asia"},{"key":"2816_CR24","first-page":"100907","volume":"41","author":"Y Huo","year":"2023","unstructured":"Huo Y, Chen B, Lian Q, Wang S, Liu L, Lu D, Qu Y, Zheng G, Li L, Ji Y, et al. Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial. Lancet Reg Health West Pac. 2023;41:100907.","journal-title":"Lancet Reg Health West Pac"},{"issue":"Suppl1","key":"2816_CR25","first-page":"A4136741","volume":"150","author":"H Shen","year":"2024","unstructured":"Shen H, Chai M, Zhou Y. Abstract 4136741: proprotein convertase subtilisin\/kexin type 9 inhibitors and lipid reduction: a network Meta-Analysis. Circulation. 2024;150(Suppl1):A4136741\u20134136741.","journal-title":"Circulation"},{"issue":"43","key":"2816_CR26","first-page":"2996","volume":"36","author":"JJ Kastelein","year":"2015","unstructured":"Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, Blom D, Civeira F, Krempf M, Lorenzato C, et al. ODYSSEY FH I and FH II: 78 week results with Alirocumab treatment in 735 patients with heterozygous Familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996\u20133003.","journal-title":"Eur Heart J"},{"issue":"5","key":"2816_CR27","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1253\/circj.CJ-14-0130","volume":"78","author":"A Hirayama","year":"2014","unstructured":"Hirayama A, Honarpour N, Yoshida M, Yamashita S, Huang F, Wasserman SM, Teramoto T. Effects of Evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk\u2013primary results from the phase 2 YUKAWA study. Circ J. 2014;78(5):1073\u201382.","journal-title":"Circ J"},{"issue":"9753","key":"2816_CR28","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive Lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"issue":"2","key":"2816_CR29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.acvd.2020.11.006","volume":"114","author":"M Farnier","year":"2021","unstructured":"Farnier M, Zeller M, Masson D, Cottin Y. Triglycerides and risk of atherosclerotic cardiovascular disease: an update. Arch Cardiovasc Dis. 2021;114(2):132\u20139.","journal-title":"Arch Cardiovasc Dis"},{"issue":"4","key":"2816_CR30","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jacl.2020.04.009","volume":"14","author":"T Aberra","year":"2020","unstructured":"Aberra T, Peterson ED, Pagidipati NJ, Mulder H, Wojdyla DM, Philip S, Granowitz C, Navar AM. The association between triglycerides and incident cardiovascular disease: what is optimal? J Clin Lipidol. 2020;14(4):438\u2013e447433.","journal-title":"J Clin Lipidol"},{"issue":"24","key":"2816_CR31","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1016\/j.jacc.2021.04.058","volume":"77","author":"PP Toth","year":"2021","unstructured":"Toth PP. Triglycerides and atherosclerosis: bringing the association into sharper focus. J Am Coll Cardiol. 2021;77(24):3042\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"2816_CR32","doi-asserted-by":"publisher","first-page":"117312","DOI":"10.1016\/j.atherosclerosis.2023.117312","volume":"383","author":"V Raja","year":"2023","unstructured":"Raja V, Aguiar C, Alsayed N, Chibber YS, ElBadawi H, Ezhov M, Hermans MP, Pandey RC, Ray KK, Tokg\u00f6zoglu L, et al. Non-HDL-cholesterol in dyslipidemia: review of the state-of-the-art literature and outlook. Atherosclerosis. 2023;383:117312.","journal-title":"Atherosclerosis"},{"issue":"Suppl 1","key":"2816_CR33","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1016\/j.ihj.2023.12.001","volume":"76","author":"K Singh","year":"2024","unstructured":"Singh K, Prabhakaran D. Apolipoprotein B - An ideal biomarker for atherosclerosis? Indian Heart J. 2024;76(Suppl 1):S121\u20139.","journal-title":"Indian Heart J"},{"key":"2816_CR34","doi-asserted-by":"crossref","unstructured":"Behbodikhah J, Ahmed S, Elyasi A, Kasselman LJ, De Leon J, Glass AD, Reiss AB. Apolipoprotein B and cardiovascular disease: biomarker and potential therapeutic target. Metabolites 2021, 11(10).","DOI":"10.3390\/metabo11100690"},{"issue":"2","key":"2816_CR35","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","volume":"75","author":"VA Bittner","year":"2020","unstructured":"Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Hanotin C, et al. Effect of Alirocumab on Lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol. 2020;75(2):133\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2816_CR36","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O\u2019Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, \u010ce\u0161ka R, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483\u201392.","journal-title":"Circulation"},{"issue":"2","key":"2816_CR37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamacardio.2020.3151","volume":"6","author":"P Deedwania","year":"2021","unstructured":"Deedwania P, Murphy SA, Scheen A, Badariene J, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, Giugliano RP. Efficacy and safety of PCSK9 Inhibition with Evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving Statin therapy: secondary analysis from the FOURIER randomized clinical trial. JAMA Cardiol. 2021;6(2):139\u201347.","journal-title":"JAMA Cardiol"},{"issue":"3","key":"2816_CR38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2174\/1566524053766086","volume":"5","author":"MR Taskinen","year":"2005","unstructured":"Taskinen MR. Type 2 diabetes as a lipid disorder. Curr Mol Med. 2005;5(3):297\u2013308.","journal-title":"Curr Mol Med"},{"issue":"3","key":"2816_CR39","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.4314\/ahs.v20i3.43","volume":"20","author":"T Zhou","year":"2020","unstructured":"Zhou T, Li H, Zhong H, Zhong Z, Lin S. Association of ApoE gene polymorphisms with lipid metabolism in renal diseases. Afr Health Sci. 2020;20(3):1368\u201381.","journal-title":"Afr Health Sci"},{"issue":"1\u20132","key":"2816_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jns.2008.09.034","volume":"277","author":"N Tascilar","year":"2009","unstructured":"Tascilar N, Dursun A, Ankarali H, Mungan G, Sumbuloglu V, Ekem S, Bozdogan S, Baris S, Aciman E, Cabuk F. Relationship of ApoE polymorphism with lipoprotein(a), apoa, ApoB and lipid levels in atherosclerotic infarct. J Neurol Sci. 2009;277(1\u20132):17\u201321.","journal-title":"J Neurol Sci"},{"issue":"1","key":"2816_CR41","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/heartjnl-2021-320708","volume":"109","author":"SA Di Fusco","year":"2022","unstructured":"Di Fusco SA, Arca M, Scicchitano P, Alonzo A, Perone F, Gulizia MM, Gabrielli D, Oliva F, Imperoli G, Colivicchi F. Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target. Heart. 2022;109(1):18\u201325.","journal-title":"Heart"},{"issue":"8","key":"2816_CR42","doi-asserted-by":"publisher","first-page":"102586","DOI":"10.1016\/j.cpcardiol.2024.102586","volume":"49","author":"Z Afzal","year":"2024","unstructured":"Afzal Z, Cao H, Chaudhary M, Chigurupati HD, Neppala S, Alruwaili W, Awad M, Sandesara D, Siddique M, Farman A, et al. Elevated lipoprotein(a) levels: A crucial determinant of cardiovascular disease risk and target for emerging therapies. Curr Probl Cardiol. 2024;49(8):102586.","journal-title":"Curr Probl Cardiol"},{"issue":"11","key":"2816_CR43","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1194\/jlr.R071233","volume":"57","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57(11):1953\u201375.","journal-title":"J Lipid Res"},{"key":"2816_CR44","unstructured":"Clarke R, Wright N, Lin K, Yu C, Walters RG, Lv J, Hill M, Kartsonaki C, Millwood IY, Bennett DA et al. Causal relevance of Lp(a) for coronary heart disease and stroke types in East Asian and European ancestry populations: a Mendelian randomization study. Circulation, 0(0)."},{"issue":"1","key":"2816_CR45","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s12170-025-00760-1","volume":"19","author":"S Doherty","year":"2025","unstructured":"Doherty S, Hernandez S, Rikhi R, Mirzai S, De Los Reyes C, McIntosh S, Block RC, Shapiro MD. Lipoprotein(a) as a causal risk factor for cardiovascular disease. Curr Cardiovasc Risk Rep. 2025;19(1):8.","journal-title":"Curr Cardiovasc Risk Rep"},{"issue":"9965","key":"2816_CR46","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, et al. PCSK9 Inhibition with Evolocumab (AMG 145) in heterozygous Familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331\u201340.","journal-title":"Lancet"},{"issue":"9","key":"2816_CR47","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1253\/circj.CJ-16-0387","volume":"80","author":"T Teramoto","year":"2016","unstructured":"Teramoto T, Kobayashi M, Tasaki H, Yagyu H, Higashikata T, Takagi Y, Uno K, Baccara-Dinet MT, Nohara A. Efficacy and safety of Alirocumab in Japanese patients with heterozygous Familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with Statins\u3000- ODYSSEY JAPAN randomized controlled trial. Circ J. 2016;80(9):1980\u20137.","journal-title":"Circ J"},{"issue":"16","key":"2816_CR48","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1161\/CIRCULATIONAHA.122.063399","volume":"147","author":"P Gaba","year":"2023","unstructured":"Gaba P, O\u2019Donoghue ML, Park JG, Wiviott SD, Atar D, Kuder JF, Im K, Murphy SA, De Ferrari GM, Gaciong ZA, et al. Association between achieved Low-Density lipoprotein cholesterol levels and Long-Term cardiovascular and safety outcomes: an analysis of FOURIER-OLE. Circulation. 2023;147(16):1192\u2013203.","journal-title":"Circulation"},{"key":"2816_CR49","unstructured":"Newman CB, Tobert JA. Safety and Tolerability of Lipid-Lowering Medications. Dyslipidemia: Clin Appr 2018:14."},{"issue":"8","key":"2816_CR50","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1517\/14740338.2014.932348","volume":"13","author":"AF Cicero","year":"2014","unstructured":"Cicero AF, Tartagni E, Ertek S. Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data. Exp Opin Drug Saf. 2014;13(8):1023\u201330.","journal-title":"Exp Opin Drug Saf"},{"issue":"9","key":"2816_CR51","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1080\/17425255.2020.1802426","volume":"16","author":"J-J Li","year":"2020","unstructured":"Li J-J, Liu H-H, Wu N-Q, Yeo KK, Tan K, Ako J, Krittayaphong R, Tan RS, Aylward PE, Baek SH. Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects. Expert Opin Drug Metab Toxicol. 2020;16(9):837\u201351.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"2816_CR52","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.3390\/jcm12062444","volume":"12","author":"G Bosco","year":"2023","unstructured":"Bosco G, Di Giacomo Barbagallo F, Spampinato S, Lanzafame L, Di Pino A, Piro S, Purrello F, Scicali R. Management of Statin intolerant patients in the era of novel lipid Lowering therapies: a critical approach in clinical practice. J Clin Med. 2023;12(6):2444.","journal-title":"J Clin Med"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02816-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02816-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02816-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T09:03:51Z","timestamp":1751533431000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02816-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2816"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02816-3","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies adhered to the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. The study protocols received approval from the institutional review boards or independent ethics committees, and all participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"264"}}